


PROTEOMICS 2: QUANTITATIVE

Yukun Li, Kye Nichols, March 31st, Gen 564Sp20



REVIEW: What is proteomics?






Proteomics : identify and quantify the proteome


QUIZ:

Why are protein levels important?

What biological processes are protein levels important?




Another review: What is the workflow of proteomics studies?




What are methods to study quantitative proteomics?

Chemical Label




What is iTRAQ ?

Isobaric tag for relative and absolute quantitation




What are Quantitative ways to study proteomics ?

Chemical Label




Metabolic Label




What is the general overview of SILAC?

Adaption Phase



Experiment Phase



What is the Adaption Phase of SILAC?

Medium Preparation

light




heavy




- amino acid essential for cell survival
- arginine and lysine often used
- C13, N15, H2

What is the experiment phase of SILAC?




What if you had multiple samples?

Multiplexed SILAC



What if you want to measure Post-Translational Modification?

Heavy Methyl SILAC



How does SILAC compare to iTRAQ?


Advantage

accurate relative quantification


used on complex mixture of cells

Disadvantage


Amino Acid Interchange




How to incorporate SILAC in my project?




Summary



Metabolic labelling uses organism's own metabolism to label
Where as chemical labelling introduce a chemical tag on peptides




SILAC metabolically labels samples and determine protein relative abundance by Mass Spectrometry. SILAC measure methylation and can measure multiple trials.



iTRAQ and SILAC 's advantages and disadvantages in quantitative proteomics

How do we use SILAC to study neurodegenerative disorders?






Quantitative interaction proteomics of neurodegenerative disease proteins

Hosp, F, et al, 2015


**By Kye Nichols March 31st,
2020**

What are some examples of neurodegenerative disorders?




Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Spinocerebellar Ataxia Type 1 (SCA1)

What are symptoms found in these neurodegenerative disorders?




Why was qualitative proteomics used to study neurodegenerative diseases?




Health

Proteostasis is important for healthy neuronal function

What are some molecular and cellular hallmarks of neurodegenerative diseases?



Health



Neurodegeneration

Changes in proteostasis can cause **neurodegeneration**


What proteins are linked to neurodegeneration?

AD
APP
PSEN1/2


PD
PARK2

HD
HTT

SCA1
ATXN1




What is the GAP in knowledge?



Construction of disease-associated protein interaction networks is a major challenge

What are common and **unique proteins** associated with neurodegeneration?



Why is SILAC effective for studying *neurodegeneration*?

Y2H and AP-MS are
"semiquantitative"

SILAC can differentiate
contaminants
&
specific binding partners




Fig. 1A: How was SILAC used to identify **unique proteins associated with *neurodegeneration*?**





Fig. 1D: What are unique and shared interactions between diseases according to online databases?

Enriched GO Terms


P values

	Caenorhabditis elegans (REF)		Client Text Box Input		
	#	expected	Fold Enrichment	+/-	P value
GO biological process complete					
positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response	4	.01	> 5	+	1.38E-06
positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus	4	.01	> 5	+	1.38E-06
mitochondrial unfolded protein response	7	.02	> 5	+	5.26E-13
response to unfolded protein	69	.47	.22	> 5	+ 4.03E-98
cellular response to unfolded protein	69	.47	.22	> 5	+ 4.03E-98
endoplasmic reticulum unfolded protein response	64	.43	.20	> 5	+ 2.99E-88
cellular response to topologically incorrect protein	74	.47	.23	> 5	+ 1.08E-96
ERAD pathway	8	.5	.03	> 5	+ 1.04E-07
ER-associated ubiquitin-dependent protein catabolic process	8	.5	.03	> 5	+ 1.04E-07
response to topologically incorrect protein	80	.48	.25	> 5	+ 6.14E-98
response to endoplasmic reticulum stress	77	.45	.24	> 5	+ 2.78E-90
response to misfolded protein	9	.3	.03	> 5	+ 5.13E-03
proteasome-mediated ubiquitin-dependent protein catabolic process	22	.5	.07	> 5	+ 1.58E-05
proteasomal protein catabolic process	22	.5	.07	> 5	+ 1.58E-05
response to heat	52	.11	.16	> 5	+ 3.14E-14



PANTHER Enrichment Analysis Results
(<http://pantherdb.org>)


Fig 1D: What binding partners were verified in protein interaction screening?




Evidence of **18** interactions by co-IP in transfected HEK cells

Fig. 1E: What cellular processes are bait proteins involved in?

Cellular Component



Biological Process



These proteins were bait for
SILAC transfection of HEK
cells

Fig. 1B: How was SILAC used to identify preferential binding to Ataxin-1?

ATXN1-Q30 ATXN1-Q82





Fig. 1C: How was SILAC used to identify preferential binding to Ataxin-1 mutants?

ATXN1-Q30 ATXN1-Q82






Fig. 2: How is neurodegeneration affected by Ataxin-1 mutations in Drosophila models?



RNA silenced ATXN1 forms induced Rough-Eye Phenotype(REP) *signifying NDD*

Fig. 3A: How does Gene Set Enrichment compare with quantitative proteomic analysis?





Fig. 3B: How does SNP enrichment signify NDD-association?

B

Cumulative distribution function GenADA



	GenADA + GERAD
SNP set	p-value
APP-WT	4.1E-05
APP-K670N/M671L	8.6E-07
APP combined	2.4E-08
PSEN1-WT	2.6E-01
PSEN1-A431E	9.9E-04
PSEN1 combined	6.2E-02
APP+PSEN1 combined	5.6E-05

Least significant enrichment of SNPs for WT

Fig. 4B: How did preferential binding behavior compare between disease-associated variants?





Fig. 5A: How does “Swedish” variant interact compared to wildtype?



Swedish variant is a known motivator in early-onset AD




Fig. 5B: Does the “Swedish” variant interact with LRPPRC compared to wildtype?

LRPPRC/APP interaction is affected by APP^{sw} variant in mitochondria.






Fig. 5C: How does the "Swedish" variant co-localize with LRPPRC in cells?


**APP^{sw}
mirrors
+control**




SFPQ / NONO
positive control




secondary antibodies only
negative control




APP / -
negative control




APP / LRPPRC
endogenous levels




APP / LRPPRC
siLRPPRC



APP / LRPPRC
empty vector control




APP / LRPPRC
APP-WT transfection




APP / LRPPRC
APP^{sw} transfection

Fig. 5D: How was differential binding behavior verified independently from SILAC?



Transfecting *APPsw* increased the signal compared to wild-type

What is a PLA assay?



provides high specificity and sensitivity

Fig. 5F: How do changes in protein binding domains affect interaction?

N-terminus mutations affect APP/LRPPRC interaction





Fig. 5E: How did neurodegenerative-associated protein interactions compare in human brain?

immunohistochemistry reveals **APP** and **LRPPRC** are co-expressed in healthy cells

LRPPRC is not found in amyloid plaques




Fig. 6A: How does "Swedish" mutation effect the proteome?

APPsw downregulated cellular levels
of **LRPPRC** and **SLIRP**




Fig. 6B: How does Co-expression of LRPPRC effect these results?

LRPPRC and SLIRP co-overexpression rescues mitochondrial function




Fig. 6C: How might “Swedish” variants effect the electron transport chain?

*APP*_{sw} downregulates expression of
COX1 & **LRPPRC**





Fig. 6D: How might "Swedish" variants effect oxidative stress?

Aconitase activity represents oxidative stress on mitochondria







Fig. 7: In summary, how does the "Swedish" variant promote neurodegeneration?

Oxidative stress
&
impaired electron
transport chain



References

- 1.) Hosp, F, et al., Quantitative interaction proteomics of neurodegenerative disease proteins. *Cell Rep.* 2015 May 19;11(7):1134-46. doi: 10.1016/j.celrep.2015.04.030. Epub 2015 May 71.
- 2.) Ong SE1, Mann M.
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). *Nat Protoc.* 2006;1(6):2650-60.
- 3.) Blagoev, Ong, et al., Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics (2002). Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/12118079/>
- 4.) Barabási, Gulbahce, et al., Network Medicine: A Network-based Approach to Human Disease Albert-László (2011). Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140052/>
- 5.) Kourkouta, Weij, et al., Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide (2019). Retrieved from: [https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531\(19\)30194-5.pdf](https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531(19)30194-5.pdf)